Total revenue from operations decreased by 7.6% YoY to Rs 282.5 crore during the quarter.

Core business revenue (Excl. covid & covid allied, PPP contract & hi-tech) grew by 15% YoY to Rs 245 crore in Q4 FY23. Core business volume growth for Q4FY23 was 15% on YoY basis.

Reported EBIDTA declined by 12.5% to Rs 69.2 crore in Q4 FY23 from Rs 79 crore in Q4 FY22. Reported EBIDTA margin was 24.5% in Q4 FY23 as against 25.8% in Q4 FY22.

Profit before tax in Q4 FY23 stood at Rs 41.9 crore, down by 25.8% from Rs 56.5 crore in Q4 FY22.

For the year ended 31 March 2023, Metropolis' total revenue from operations stood at Rs 1,148.2 crore as against Rs 1,228.3 crore for the year ended 31 March 2022, down by 6.5%. Net profit fell by 33.2% to Rs 143.4 crore in FY23 as compared with FY22.

Ameera Shah, promoter and managing director, Metropolis Healthcare, said: “We have been witnessing continuous uptick in our core business revenues over the last 4 quarters with volumes growing across markets.

Our revenues from North grew by approximately 30% for Q4FY23 strengthening our presence in non-core geographies & expanding our reach on Pan-India basis.

Revenue contribution from our premium wellness segment increased to 15% in Q4FY23 & witnessed a healthy growth of 43% Y-o-Y, a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers.

Going forward, we focus on our network expansion, growing our specialised & wellness segments and upgrading our IT infrastructure for enhancing the consumer experience.”

Metropolis Healthcare is a diagnostics company, with presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 175 labs, 3,675 collection centres and over 10,000 touch points.